"Raloxifene Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
| Descriptor ID |
D020849
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900.775
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Raloxifene Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Raloxifene Hydrochloride".
This graph shows the total number of publications written about "Raloxifene Hydrochloride" by people in this website by year, and whether "Raloxifene Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Raloxifene Hydrochloride" by people in Profiles.
-
Qaseem A, Forciea MA, McLean RM, Denberg TD, Barry MJ, Cooke M, Fitterman N, Harris RP, Humphrey LL, Kansagara D, McLean RM, Mir TP, Sch?nemann HJ. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017 06 06; 166(11):818-839.
-
Lubelski D, Choma TJ, Steinmetz MP, Harrop JS, Mroz TE. Perioperative Medical Management of Spine Surgery Patients With Osteoporosis. Neurosurgery. 2015 Oct; 77 Suppl 4:S92-7.
-
Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011 Jun; 127(3):681-8.
-
Karp BI, Sinaii N, Nieman LK, Silberstein SD, Stratton P. Migraine in women with chronic pelvic pain with and without endometriosis. Fertil Steril. 2011 Mar 01; 95(3):895-9.
-
Balaburski GM, Dardes RC, Johnson M, Haddad B, Zhu F, Ross EA, Sengupta S, Klein-Szanto A, Liu H, Lee ES, Kim H, Jordan VC. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol. 2010 Aug; 37(2):387-98.
-
Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health. 2008 Dec 23; 8:24.
-
DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, Schinnar R, Burgh D, Berlin M, Rubin SC, Rebbeck TR, Strom BL. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008 Sep 01; 26(25):4151-9.
-
Hayes DF. Playing the old piano: another tune for endocrine therapy? J Natl Cancer Inst. 2003 Nov 05; 95(21):1565-7.
-
Gao ZO, Gao ZP, Fields JZ, Boman BM. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells. Anticancer Res. 2002 May-Jun; 22(3):1379-83.
-
Umland EM, Rinaldi C, Parks SM, Boyce EG. The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann Pharmacother. 1999 Dec; 33(12):1315-28.